open-label BE trials maintain blindness [Study Per­for­mance]

posted by kimhuang – China, 2023-10-18 02:50 (280 d 23:29 ago) – Posting: # 23762
Views: 2,089

❝ So there are no SOP w.r.t. pre-dose concentration, abnormal PK concentration, λz estimation? Generally QA goes ahead with protocol inclusion/exclusion criteria and SOP of BA.

there's no SOP about handing these cases, case-by-case discuss in blinded data review meeting.

❝ Does BA team also have access to CRF? Then how it is blinded?

BA is blinded.

Edit: Full quote removed. Please delete everything from the text of the original poster which is not necessary in understanding your answer; see also this post #5[Helmut]

Complete thread:

UA Flag
 Admin contact
23,127 posts in 4,859 threads, 1,646 registered users;
41 visitors (0 registered, 41 guests [including 14 identified bots]).
Forum time: 02:19 CEST (Europe/Vienna)

No problem can stand the assault of sustained thinking.    Voltaire

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz